Mark Iwicki Sells 154,894 Shares of KALA BIO (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) Director Mark Iwicki sold 154,894 shares of the firm’s stock in a transaction that occurred on Thursday, October 23rd. The shares were sold at an average price of $0.81, for a total value of $125,464.14. Following the completion of the transaction, the director owned 103,540 shares of the company’s stock, valued at approximately $83,867.40. The trade was a 59.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

KALA BIO Trading Up 1.8%

KALA opened at $0.80 on Friday. KALA BIO, Inc. has a 52 week low of $0.77 and a 52 week high of $20.60. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 3.19. The stock has a market cap of $5.59 million, a PE ratio of -0.12 and a beta of -2.10. The business has a 50 day moving average of $9.01 and a 200-day moving average of $6.29.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.82) by $0.11. Equities research analysts predict that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Institutional Trading of KALA BIO

Large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in shares of KALA BIO in the second quarter worth $62,000. Readystate Asset Management LP bought a new stake in shares of KALA BIO in the first quarter worth $243,000. Geode Capital Management LLC grew its holdings in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock worth $268,000 after acquiring an additional 1,534 shares during the period. AIGH Capital Management LLC grew its holdings in shares of KALA BIO by 61.9% in the first quarter. AIGH Capital Management LLC now owns 196,350 shares of the company’s stock worth $1,125,000 after acquiring an additional 75,048 shares during the period. Finally, Woodline Partners LP bought a new stake in shares of KALA BIO in the first quarter worth $1,483,000. Institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen lowered KALA BIO from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Lifesci Capital lowered KALA BIO from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of KALA BIO in a report on Wednesday, October 8th. Oppenheimer lifted their target price on KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Finally, LADENBURG THALM/SH SH lowered KALA BIO from a “buy” rating to a “neutral” rating in a report on Monday, September 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.38.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.